Kaposi's sarcoma herpesvirus seroprevalence among blood donors in Uganda.

IF 2.5 3区 医学 Q2 HEMATOLOGY
Transfusion Pub Date : 2025-04-02 DOI:10.1111/trf.18236
Tait Huso, Jodie L White, Dorothy Kyeyune, Angela D'Adamo, Nazzarena Labo, Wendell Miley, Ezra Musisi, Khan Moses, Ronnie Kasirye, Irene Lubega, Hellen Wambongo Musana, Priscilla Eroju, Mahnaz Motevalli, Raymond Goodrich, M Kate Grabowski, Thomas C Quinn, Paul M Ness, Heather A Hume, Henry Ddungu, Aggrey Dhabangi, Evan M Bloch, Mary Glenn Fowler, Philippa Musoke, Denise Whitby, Aaron A R Tobian
{"title":"Kaposi's sarcoma herpesvirus seroprevalence among blood donors in Uganda.","authors":"Tait Huso, Jodie L White, Dorothy Kyeyune, Angela D'Adamo, Nazzarena Labo, Wendell Miley, Ezra Musisi, Khan Moses, Ronnie Kasirye, Irene Lubega, Hellen Wambongo Musana, Priscilla Eroju, Mahnaz Motevalli, Raymond Goodrich, M Kate Grabowski, Thomas C Quinn, Paul M Ness, Heather A Hume, Henry Ddungu, Aggrey Dhabangi, Evan M Bloch, Mary Glenn Fowler, Philippa Musoke, Denise Whitby, Aaron A R Tobian","doi":"10.1111/trf.18236","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Kaposi's sarcoma herpesvirus (KSHV) causes a life-long infection that can progress to several types of KSHV-associated diseases. There is evidence for transfusion transmission of KSHV. In endemic regions, such as sub-Saharan African, KSHV seroprevalence is >40%. However, previous studies of blood donors utilized immunoassays that detect KSHV-associated disease-specific antigens, which may underestimate the true burden of KSHV in a healthy population.</p><p><strong>Study design and methods: </strong>We utilized samples from an on-going transfusion transmitted infection clinical trial to estimate the seroprevalence of KSHV among 4921 blood donations from healthy donors in Uganda collected between October 2019 and December 2022. A multiplexed bead-based assay was used to measure plasma IgG against five antigens encoded by the K8.1, K10.5, ORF73, ORF38, and ORF25 genes of KSHV. Significant associations between donor characteristics and seroprevalence were assessed by chi-square tests.</p><p><strong>Results: </strong>Overall, KSHV seroprevalence was 69.1%. Seroprevalence was higher in units collected from older donors compared with younger donors and male donors (71.9% [95% confidence interval (CI) = 70.4%-73.3%]) compared with female donors (61.3% [95% CI = 58.6%-64.0%]; p < .001). KSHV seroprevalnce was higher among units collected from donors positive for T. pallidum (82.5% [95% CI = 73.8%-89.3%]) compared with units collected from donors who were negative (68.8% [95% CI = 67.5%-70.1%]; p < .001). KSHV seroprevalence was higher in units that tested positive for HIV, HBV, or HCV, though these results were not statistically significant.</p><p><strong>Conclusion: </strong>Given the high seroprevalence and limited availability of lab assays that detect active KSHV infections, methods such as leukoreduction or pathogen reduction should be considered to potentially reduce the risk of transfusion transmission of KSHV.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transfusion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/trf.18236","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Kaposi's sarcoma herpesvirus (KSHV) causes a life-long infection that can progress to several types of KSHV-associated diseases. There is evidence for transfusion transmission of KSHV. In endemic regions, such as sub-Saharan African, KSHV seroprevalence is >40%. However, previous studies of blood donors utilized immunoassays that detect KSHV-associated disease-specific antigens, which may underestimate the true burden of KSHV in a healthy population.

Study design and methods: We utilized samples from an on-going transfusion transmitted infection clinical trial to estimate the seroprevalence of KSHV among 4921 blood donations from healthy donors in Uganda collected between October 2019 and December 2022. A multiplexed bead-based assay was used to measure plasma IgG against five antigens encoded by the K8.1, K10.5, ORF73, ORF38, and ORF25 genes of KSHV. Significant associations between donor characteristics and seroprevalence were assessed by chi-square tests.

Results: Overall, KSHV seroprevalence was 69.1%. Seroprevalence was higher in units collected from older donors compared with younger donors and male donors (71.9% [95% confidence interval (CI) = 70.4%-73.3%]) compared with female donors (61.3% [95% CI = 58.6%-64.0%]; p < .001). KSHV seroprevalnce was higher among units collected from donors positive for T. pallidum (82.5% [95% CI = 73.8%-89.3%]) compared with units collected from donors who were negative (68.8% [95% CI = 67.5%-70.1%]; p < .001). KSHV seroprevalence was higher in units that tested positive for HIV, HBV, or HCV, though these results were not statistically significant.

Conclusion: Given the high seroprevalence and limited availability of lab assays that detect active KSHV infections, methods such as leukoreduction or pathogen reduction should be considered to potentially reduce the risk of transfusion transmission of KSHV.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Transfusion
Transfusion 医学-血液学
CiteScore
4.70
自引率
20.70%
发文量
426
审稿时长
1 months
期刊介绍: TRANSFUSION is the foremost publication in the world for new information regarding transfusion medicine. Written by and for members of AABB and other health-care workers, TRANSFUSION reports on the latest technical advances, discusses opposing viewpoints regarding controversial issues, and presents key conference proceedings. In addition to blood banking and transfusion medicine topics, TRANSFUSION presents submissions concerning patient blood management, tissue transplantation and hematopoietic, cellular, and gene therapies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信